Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles S Eby

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Clinical Chemistry|August 30, 2017
CommentaryCharles S Eby
Clinical Chemistry|March 15, 2013
Warfarin replacements: good for patients, challenging for laboratoriesCharles S Eby
Clinical Chemistry|February 24, 2009
Counterpoint: pharmacogenetic-based initial dosing of warfarin: not ready for prime timeCharles S Eby
Hematology. American Society of Hematology. Education Program|November 21, 2007
Bleeding and thrombosis risks in plasma cell dyscrasiasCharles S Eby
Current Opinion in Hematology|July 17, 2004
Recombinant activated factor VII for non-hemophiliac bleeding patientsErik J Uhlmann, Charles S Eby
Advances in Experimental Medicine and Biology|August 8, 2024
Zoonotic Bacterial Infections Triggering Cytokine Storm SyndromeZaher K Otrock, Charles S Eby
Journal of Thrombosis and Thrombolysis|February 5, 2004
Pharmacogenetics and anticoagulant therapyBrian F Gage, Charles S Eby
Clinical Chemistry|April 1, 2008
Evaluation of a prolonged prothrombin timeJoshua L Hood, Charles S Eby
American Journal of Hematology|December 4, 2014
Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosisZaher K Otrock, Charles S Eby
Clinical Chemistry|May 27, 2003
Lamellar body count in amniotic fluid: a comparative study of four different hematology analyzersArpad Szallasi, Ann M Gronowski, Charles S Eby
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Clinical Chemistry|August 30, 2017
CommentaryCharles S Eby
Clinical Chemistry|March 15, 2013
Warfarin replacements: good for patients, challenging for laboratoriesCharles S Eby
Clinical Chemistry|February 24, 2009
Counterpoint: pharmacogenetic-based initial dosing of warfarin: not ready for prime timeCharles S Eby
Hematology. American Society of Hematology. Education Program|November 21, 2007
Bleeding and thrombosis risks in plasma cell dyscrasiasCharles S Eby
Current Opinion in Hematology|July 17, 2004
Recombinant activated factor VII for non-hemophiliac bleeding patientsErik J Uhlmann, Charles S Eby
Advances in Experimental Medicine and Biology|August 8, 2024
Zoonotic Bacterial Infections Triggering Cytokine Storm SyndromeZaher K Otrock, Charles S Eby
Journal of Thrombosis and Thrombolysis|February 5, 2004
Pharmacogenetics and anticoagulant therapyBrian F Gage, Charles S Eby
Clinical Chemistry|April 1, 2008
Evaluation of a prolonged prothrombin timeJoshua L Hood, Charles S Eby
American Journal of Hematology|December 4, 2014
Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosisZaher K Otrock, Charles S Eby
Clinical Chemistry|May 27, 2003
Lamellar body count in amniotic fluid: a comparative study of four different hematology analyzersArpad Szallasi, Ann M Gronowski, Charles S Eby
Pageof 6